Broad Genetic Testing for NSCLC May Not Improve Survival

Compared with routine genetic testing, no improvement seen in unadjusted mortality rate
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pulmonology, Journal, Source Type: news

Related Links:

Authors: Simsek FS, Arslan M, Dag Y Abstract In some non-small cell lung cancer (NSCLC) patients, lipid-poor adrenal adenomas cannot be adequately differentiated from metastases using imaging methods. Invasive diagnostic procedures also have a low negative predictive value (NPV) in such cases. The current study aims to establish a specific and clinically practical metabolic parameter for lipid-poor adrenal lesions (ALs) in NSCLC patients. This diagnostic approach may prevent unnecessary abdominal enhanced computed tomography (CT), magnetic resonance imaging, or invasive diagnostic procedures. Sixty-four NSCLC patie...
Source: Bosnian Journal of Basic Medical Sciences - Category: General Medicine Tags: Bosn J Basic Med Sci Source Type: research
Conditions:   Advanced and/or Metastatic Solid Tumors;   Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer;   Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma Interventions:   Drug: INCMGA00012;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel Sponsor:   Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 18 April 2019Source: The Annals of Thoracic SurgeryAuthor(s): David B. Nelson, Reza J. Mehran, Kyle G. Mitchell, Ravi Rajaram, Arlene M. Correa, Roland L. Bassett, Mara B. Antonoff, Wayne L. Hofstetter, Jack A. Roth, Boris Sepesi, Stephen G. Swisher, Garrett L. Walsh, Ara A. Vaporciyan, David C. RiceAbstractBackgroundIt is unclear whether the enhanced dexterity and visualization of the surgical robot lessens morbidity and influences staging or survival. We compared outcomes of robotic-assisted lobectomy (RAL) with thoracoscopic (VAL) or open lobectomy (OL) of non-small cell lung cancer (N...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
AbstractBackgroundThe aim of this study was to discuss indications and outcomes for conversion to thoracotomy during thoracoscopic lobectomy.Materials and methodsPatients who underwent lobectomy for non-small cell lung cancer between January 2012 and December 2016 were evaluated retrospectively. The study included 129 patients who underwent video-assisted thoracoscopic lobectomy (group-V) and 18 patients converted from thoracoscopic lobectomy to thoracotomy due to unexpected intraoperative complications (group-T).ResultsThe two patient groups showed no statistical differences in terms of demographic characteristics. Causes...
Source: General Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
This study aimed to investigate the role and regulatory mechanism of CypB in NSCLC progression. The expression levels of CypB was detected in NSCLC samples and cell lines by ELISA, western blot and immunohistochemistry assay. In addition, CCK8, colony formation, scratch and transwell assays were used to evaluate the proliferation, migration and invasion of A549 cells with CypB silencing. The expression of angiogenesis related proteins and pathway-related factors were detected by western blot. In NSCLC samples, CypB expression was upregulated. The expression of CypB was significantly reduced in the siRNA-cyclophilin B group...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Conclusions: The current evidence suggests that DCVB6 injection combined with chemotherapy could increase objective response rate and Karnofsky performance score, improve clinical symptoms, and reduce side effects caused by chemotherapy in patients with NSCLC. However, these results should be carefully interpreted due to the low-quality methodology and the small sample sizes of the trials, and our conclusions should be verified by high-quality, large-scale, double-blinded RCTs. PMID: 30992710 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
AMP-activated protein kinase α1 serves a carcinogenic role via regulation of vascular endothelial growth factor expression in patients with non-small cell lung cancer. Oncol Lett. 2019 May;17(5):4329-4334 Authors: Hui GD, Xiu WY, Yong C, Yuan CB, Jun Z, Jun GJ, Jun YJ, Xiang XX, Wei HS, Feng ML Abstract AMP-activated protein kinase α1 (AMPK α1) is involved in the tumorigenesis of various cancer types. However, the role of AMPK α1 in non-small cell lung cancer (NSCLC) remains unclear. In the present study, 99 NSCLC tumor tissues and paired normal tissues were obtained. The expres...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
For stage IIIB lung cancer, if the chemotherapy regimen is paclitaxel plus carboplatin, do MedOncs complete 2 cycles of consolidative paclitaxel plus carboplatin q21 days and then start durvalumab? Or forgo consolidatiive pac/carbo altogether? Any data to support either approach? Thanks.
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Radiation Oncology Source Type: forums
Publication date: 16 April 2019Source: Cell Reports, Volume 27, Issue 3Author(s): Hyejin Choi, Jiehui Deng, Shuai Li, Tarik Silk, Lauren Dong, Elliott J. Brea, Sean Houghton, David Redmond, Hong Zhong, Jonathan Boiarsky, Esra A. Akbay, Paul D. Smith, Taha Merghoub, Kwok-Kin Wong, Jedd D. WolchokSummaryKRAS is one of the driver oncogenes in non-small-cell lung cancer (NSCLC) but remains refractory to current modalities of targeted pathway inhibition, which include inhibiting downstream kinase MEK to circumvent KRAS activation. Here, we show that pulsatile, rather than continuous, treatment with MEK inhibitors (MEKis) mainta...
Source: Cell Reports - Category: Cytology Source Type: research
Lung cancer remains the leading cause of cancer-related death worldwide, with a disappointing five-year survival rate of approximately 15% [1]. Due to the advanced stage at the time of diagnosis, the prognosis is often poor, and therapeutic options are limited. The presence of multiple metastases renders surgical resection inadequate, and resistance to treatment is a growing problem. Non-small cell lung cancer (NSCLC) represents the most common group of lung cancer (approximately 80% of cases), and activating mutations in receptor tyrosine kinases (RTKs), e.g., in the Epidermal Growth Factor Receptor (EGFR) gene, are frequ...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer & Oncology | Genetics | Non-Small Cell Lung Cancer | Pathology